ER+/HER2- metastatic breast cancer: ESMO Breast Cancer 2026 Satellite Symposium highlightsExperts discuss 2nd line+ treatment strategies and sequencing following ET + CDK4/6i in endocrine therapy–eligible patients with ER+/HER2− mBCTopics include: >> Overview of current ESMO guidelines >> Intrinsic and acquired endocrine resistance after 1L ET + CDK4/6i >> Role of biomarker-selected endocrine-based therapies and key clinical trial data >> Clinical relevance of 𝐸𝑆𝑅1 mutations and testing strat

all breast and no brains

In the sequel to her last article, Hannah shares a deeply personal look at her 50–year journey navigating gender, labels, and finding community. What happens when the rules don't fit who you are? Link in bio! 💄👠@HannahTGirlMN